Study of Poziotinib in Patients With HER2-Positive Metastatic Breast Cancer
Status:
Completed
Trial end date:
2020-04-07
Target enrollment:
Participant gender:
Summary
The purpose of this study is to establish the dose regimen and evaluate the preliminary
efficacy and the safety/tolerability of poziotinib in patients with HER2-positive metastatic
breast cancer who have received at least 2 prior HER2-directed treatment regimens.